The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of imaging frequency on progression free survival in Alliance clinical trials enrolling patients with untreated follicular lymphoma.
 
Sarah C. Rutherford
Consulting or Advisory Role - ADC Therapeutics; Genmab; Karyopharm Therapeutics; Kite, a Gilead company; Seagan
Research Funding - Genentech (Inst); Karyopharm Therapeutics (Inst)
 
Jun Yin
Employment - Mayo Clinic
 
Levi D Pederson
No Relationships to Disclose
 
Kristie A. Blum
Honoraria - American Society of Hemotology; Leidos Biomedical Research/NCI
Research Funding - BMSi (Inst); Genentech/Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - American Society of Hemotology
 
Peter Martin
Consulting or Advisory Role - ADC Therapeutics; BeiGene; Bristol-Myers Squibb/Celgene; Epizyme; Janssen; Karyopharm Therapeutics; Kite/Gilead; Merck; MorphoSys; Takeda; Verastem
Research Funding - Karyopharm Therapeutics (Inst)
 
Sin-Ho Jung
Consulting or Advisory Role - Samsung
 
Barbara Grant
No Relationships to Disclose
 
Cara Rosenbaum
Stock and Other Ownership Interests - Merck/Organon
Consulting or Advisory Role - Akcea Therapeutics; GlaxoSmithKline; Janssen Biotech; Oncopeptides; Takeda
Research Funding - Amgen; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics
 
Bruce D. Cheson
Leadership - SymBio Pharmaceuticals
Consulting or Advisory Role - Abbvie; Celgene; Epizyme; Gilead Sciences; Imaging Endpoints; Karyopharm Therapeutics; Lilly; MEI Pharma; Morphosys; Parexel; Pharmacyclics/Janssen; SymBio Pharmaceuticals; Tessa Therapeutics; TG Therapeutics
Speakers' Bureau - BeiGene; Lilly; MorphoSys/Incyte; TG Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Seagen (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - SymBio Pharmaceuticals
 
Nancy L. Bartlett
Consulting or Advisory Role - ADC Therapeutics; Foresight Diagnostics; Kite, a Gilead company; Roche/Genentech; Seagen
Research Funding - ADC Therapeutics (Inst); Autolus (Inst); Bristol-Myers Squibb/Celgene; Forty Seven (Inst); Janssen (Inst); Kite, a Gilead company; Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Sumithra J. Mandrekar
Honoraria - BeiGene
Consulting or Advisory Role - Flatiron Health; Harbinger Oncology, Inc
Other Relationship - Beigene
 
John Paul Leonard
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Calithera Biosciences; Celgene; Constellation Pharmaceuticals; Eisai; Epizyme; Genentech/Roche; Genmab; Gilead Sciences; Grail; Incyte; Janssen Oncology; Karyopharm Therapeutics; Lilly; MEI Pharma; Merck; Morphosys; MustangBio; Novartis; Pfizer; Seagen; Second Genome; Sutro Biopharma
Research Funding - Alliance for Clinical Trials in Oncology (Inst); Celgene (Inst); Epizyme (Inst); Genentech (Inst); Janssen Oncology (Inst); National Cancer Institute (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - BeiGene